Vyome (NASDAQ:HIND – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.13) EPS for the quarter, FiscalAI reports. The business had revenue of $0.06 million during the quarter. Vyome had a negative net margin of 3,024.84% and a negative return on equity of 197.33%.
Vyome Stock Down 3.4%
NASDAQ:HIND traded down $0.06 during midday trading on Friday, hitting $1.57. The stock had a trading volume of 1,827 shares, compared to its average volume of 256,016. Vyome has a one year low of $1.53 and a one year high of $5.88. The company has a market capitalization of $11.06 million, a price-to-earnings ratio of -0.47 and a beta of 1.51. The stock has a 50-day moving average of $1.90 and a 200 day moving average of $2.20.
Analysts Set New Price Targets
Several analysts have recently weighed in on HIND shares. Chardan Capital started coverage on Vyome in a research report on Thursday, September 3rd. They set a “buy” rating and a $3.50 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a research note on Tuesday, October 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.50.
Read Our Latest Analysis on HIND
About Vyome
Vyome Holdings, Inc. (NASDAQ:HIND) is a biotechnology company focused on developing therapies for inflammatory and infectious diseases of the skin. The company applies research in the skin microbiome and immune modulation to identify potential treatments for conditions that can be difficult to manage with existing therapies. Vyome’s development programs have included topical drug candidates for dermatological conditions such as acne vulgaris and atopic dermatitis. Its lead programs are intended to address underlying biological mechanisms, including harmful bacterial activity and inflammation, rather than relying solely on conventional broad-spectrum antimicrobial approaches.
Featured Stories
- Five stocks we like better than Vyome
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.
